Moderna COVID-19 shot cleared in Canada for children aged 6 to 11 years
Maddie Meyer/Getty Images News


Moderna (NASDAQ:MRNA) announced on Thursday that Health Canada approved its COVID-19 vaccine, branded as Spikevax, for immunization against COVID-19 in children aged 6 to11 years.
The regulator has approved a two-dose regimen of the vaccine at 50 Âµg per dose, half the level of dosage recommended for adults.

Recently, Australia and the European Union also authorized the vaccine for the age group.
"Health Canada was the first regulator to fully approve our COVID-19 vaccine, and we are pleased they have taken this important step to expand this authorization to children aged 6 to11 years," Chief Executive StÃ©phane Bancel noted. 
In the U.S., only Pfizer (PFE)/ BioNTech (BNTX) COVID-19 shot is available for use in the age group.